Seres Therapeutics (NASDAQ: MCRB) Stock Gains Momentum Ahead of Q4 Earnings
Investors are almost always on the prowl for the latest financial results, and given the announcement from the company yesterday, it is likely that the Seres Therapeutics Inc. stock is going to be on the radars of investors this morning. In this feature, we take a closer look at the announcement.
Results on March 13
In the news release from Seres Therapeutics yesterday, the company announced that it would release the financial results in question on March 13, 2025. However, more importantly, the management would also participate in a conference call on the same day at 8-30 am Eastern Time to discuss the fourth fiscal quarter and yearly financial results. Additionally, Seres Therapeutics would also provide key business updates. In addition to that, a webcast of the call would also be released for future reference.
Further Information
Earlier on in the week, the company also announced that it had received constructive feedback pertaining to its Type B breakthrough Therapy designation from the United States Food and Drug Administration. The feedback was about the development strategy that had been adopted by the company for the product.
Technicals
| +/- EMA(20) | 0.78 (-1.94%) |
| +/- SMA(50) | 0.82 (-6.72%) |
| +/- SMA(200) | 0.88 (-13.08%) |
| 5-Day Perf. | +1.96% |
| 1-Month Perf. | -3.24% |
| 3-Month Perf. | -6.11% |
| 6-Month Perf. | -15.01% |
| YTD Perf. | -7.95% |
| 1-Year Perf. | -27.84% |
| RSI(14) | 47.03 |
| ATR(14) | 0.06 |
| ADX(14) | 17.06 |
| Beta (5Y) | 1.10 |
